News & Updates

Low-dose drug combinations that incorporate between three and four blood pressure (BP)-lowering medications appear to be well tolerated and effective for the initial or early management of hypertension, according to the results of a systematic review and meta-analysis.

The use of rivaroxaban in nonhospitalized patients with symptomatic COVID-19 falls short of reducing the composite endpoint of venous and arterial thrombotic events, hospitalization, and death, according to data from PREVENT-HD*.

P2B001, an investigational drug formulation that combines extended release (ER) doses of pramipexole and rasagiline, shows promise in managing Parkinson’s Disease (PD), conferring symptom control similar to that achieved with the marketed ER pramipexole while reducing the troublesome side effect of excessive daytime sleepiness.

Poor outcomes hound several patients with chronic kidney disease (CKD) who develop intracerebral haemorrhage, reveals a study presented at the recent AAN 2023.

A study from Singapore demonstrated the usefulness of a systematic programme using combined microbiologic, serologic, and genomic criteria to assess possible COVID-19 reinfection cases.

Women with heart disease are at increased risk of developing hypertension in the decades after pregnancy compared with those without heart disease, as reported in a retrospective study.